Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.

about

MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.

P2860

Q47112808-34674015-E0D5-4B9C-B2D4-E73499E30357

P2860

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.

Item

http://www.wikidata.org/entity/Q50073578

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Design and characterization of ...... i-VEGF DARPin® drug candidate.

@en

Design and characterization of ...... i-VEGF DARPin® drug candidate.

@nl

type

Item

label

Design and characterization of ...... i-VEGF DARPin® drug candidate.

@en

Design and characterization of ...... i-VEGF DARPin® drug candidate.

@nl

prefLabel

Design and characterization of ...... i-VEGF DARPin® drug candidate.

@en

Design and characterization of ...... i-VEGF DARPin® drug candidate.

@nl

P1476

Design and characterization of ...... ti-VEGF DARPin® drug candidate

@en

P2093

Andreas Cornelius

http://www.w3.org/2001/XMLSchema#string

Christof Zitt

http://www.w3.org/2001/XMLSchema#string

Gaby Tresch

http://www.w3.org/2001/XMLSchema#string

Ignacio Dolado

http://www.w3.org/2001/XMLSchema#string

Johan Abram Saliba

http://www.w3.org/2001/XMLSchema#string

Karl Proba

http://www.w3.org/2001/XMLSchema#string

Michael T Stumpp

http://www.w3.org/2001/XMLSchema#string

Talitha R Bakker

http://www.w3.org/2001/XMLSchema#string

Thomas Göttler

http://www.w3.org/2001/XMLSchema#string

Ulrike Fiedler

http://www.w3.org/2001/XMLSchema#string

P2860

Challenges and opportunities for non-antibody scaffold drugs

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

High-affinity binders selected from designed ankyrin repeat protein libraries

Tumor angiogenesis

Angiogenesis as a therapeutic target

Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins.

Engineering novel binding proteins from nonimmunoglobulin domains.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

P304

1262-1269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2017.1305529

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29035637

http://www.w3.org/2001/XMLSchema#string

P932

5680794

http://www.w3.org/2001/XMLSchema#string

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.

about

P2860

P2860

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932